Active pulmonary tuberculosis: Role for amikacin in early treatment.
暂无分享,去创建一个
F. Mechaï | N. Vignier | O. Bouchaud | M. Gousseff | J. Figoni | C. Leblanc | Nicolas Vignier | Olivier Bouchaud
[1] D. Mitchison,et al. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. , 2015, The American review of respiratory disease.
[2] D. Che,et al. [Epidemiology of tuberculosis]. , 2012, La Revue du praticien.
[3] D. Che,et al. [Epidemiology of tuberculosis in France in 2008]. , 2011, Medecine et maladies infectieuses.
[4] A. van Belkum,et al. Time-kill kinetics of anti-tuberculosis drugs, and emergence of resistance, in relation to metabolic activity of Mycobacterium tuberculosis. , 2010, The Journal of antimicrobial chemotherapy.
[5] J. Chevillotte. Surveiller et prévenir les infections associées aux soins , 2010 .
[6] T. Udou. Comparative Evaluation of the In Vitro Antimycobacterial Activities of Six Aminoglycoside Antibiotics Using an Agar Dilution Method , 2006, Journal of chemotherapy.
[7] D. Curran‐Everett,et al. Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[8] R. Altena. Hearing loss and nephrotoxicity treatment in patients with in long-term aminoglycoside tuberculosis , 2002 .
[9] P. Brouqui,et al. Clinical and microbiological efficacy of adjunctive salvage therapy with inhaled aminoglycosides in a patient with refractory cavitary pulmonary tuberculosis. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[10] M. Iseman,et al. Some healthy skepticism about inhaled therapy for tuberculosis. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[11] D. Mitchison,et al. The early bactericidal activity of amikacin in pulmonary tuberculosis. , 2001, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[12] J. Justman,et al. Factors influencing time to sputum conversion among patients with smear-positive pulmonary tuberculosis. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[13] C. Chan,et al. In-vitro activities of aminoglycoside-aminocyclitols against mycobacteria. , 1997, The Journal of antimicrobial chemotherapy.
[14] Pulmonary Infections. Treatment of Tuberculosis and Tuberculosis Infection in Adults and Children , 1998 .
[15] D. Snider,et al. Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention. , 1994, American journal of respiratory and critical care medicine.
[16] L. Gabbasova,et al. Global tuberculosis report (2014) , 2014 .
[17] C-L. Hsu,et al. Adding moxifloxacin is associated with a shorter time to culture conversion in pulmonary tuberculosis. , 2010, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[18] P. D. de Jager,et al. Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis. , 2002, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[19] L. Sacks,et al. Adjunctive salvage therapy with inhaled aminoglycosides for patients with persistent smear-positive pulmonary tuberculosis. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.